Find Comparable Stocks for Gilead Sciences, Inc.
Gilead Sciences, Inc.
GILD - NMSGilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi.
Income Statement
Financial Ratios
Growth
AbbVie Inc.
ABBV - NYQAbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Gilead Sciences, Inc. specializes in antiviral drugs and has a robust portfolio, comparable to AbbVie’s offerings in the pharmaceutical preparations industry. Both companies are known for their innovative research and development.
correlation
Measures how closely the two stocks' prices move together over time. A high correlation suggests similar market reactions and investor sentiment.
Pearson Correlation: 23%
R-squared: 5%
This indicates a negligible relationship between the price movements of these stocks.
network
Evaluates the overlap in business networks, partnerships, and industry relationships, indicating similarity in market positioning and competitive landscape.
- Common comparables: 5
- ABBV in GILD's comparables: Yes
- GILD in ABBV's comparables: Yes
A high score suggests the companies are often compared to each other and share many industry peers, indicating similar competitive environments and market perceptions.
financials
Compares key financial metrics to assess operational similarity and financial health.
- Revenue Growth: 6% vs 6%
- Profit Margin: 8% vs 2%
- ROE: 62% vs 2%
- Operating Margin: 33% vs 33%
- Revenue (TTM): $56.3B vs $28.8B
A high score indicates similar financial performance, efficiency, and growth trajectories, suggesting comparable business models and market positions.
size
Evaluates similarity in market capitalization, which can indicate comparable market influence, investor interest, and resource availability.
Market Cap: $378.3B vs $143.8B
Size Category: Mega Cap vs Large Cap
A high score suggests the companies are in the same size category, facing similar challenges and opportunities in terms of market presence and financial flexibility.
valuation
Compares valuation metrics to assess if the stocks are valued similarly by the market, indicating comparable investor expectations and perceived growth potential.
- P/E Ratio: 89.29 vs 303.89
- P/B Ratio: 113.77 vs 7.39
- EV/EBITDA: 29.50 vs 35.64
- Forward P/E: 17.48 vs 14.51
- PEG Ratio: 0.45 vs 0.61
A high score indicates that the market values these companies similarly relative to their financials, suggesting comparable growth expectations and risk profiles.
sector
Compares the sector and industry classification of both companies, allowing for partial matches.
- Sector: LIFE SCIENCES vs LIFE SCIENCES
- Industry: PHARMACEUTICAL PREPARATIONS vs BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
A high score indicates that the companies operate in similar business areas, facing comparable market conditions, regulatory environments, and industry trends. Partial matches are considered for more nuanced comparisons.
analyst ratings
Compares the consensus of analyst opinions on both stocks.
- ABBV Rating: Buy
- GILD Rating: Buy
A high score suggests that analysts view both stocks similarly in terms of their future prospects and investment potential.
geo
Evaluates the geographical similarity of the companies based on country, currency, exchange, and address.
- ABBV Country: USA
- GILD Country: USA
- Currency: USD vs USD
- Exchange: NYQ vs NMS
A high score indicates that both companies operate in similar geographical markets, facing comparable economic conditions, regulations, and market dynamics.
volatility
Compares price volatility and risk profiles, indicating similarity in market behavior, risk, and potential for price swings.
- ABBV Beta: 0.60 (Low)
- GILD Beta: 0.24 (No Correlation)
A high score suggests both stocks have similar sensitivity to market movements, implying comparable risk levels and potential for both gains and losses.
business similarity
Assesses the similarity of the companies' business models, products, and services.
This score is based on an analysis of the companies' business descriptions, major products, and revenue streams.
A high score indicates that the companies have similar core businesses, target markets, and revenue generation strategies.
momentum
Compares recent price momentum, showing similarity in short-term market performance and investor sentiment.
- ABBV Price vs 200-day MA: 116.93%
- GILD Price vs 200-day MA: 137.36%
A high score indicates both stocks are experiencing similar price trends relative to their recent history, suggesting comparable market enthusiasm or concern.
dividend
Compares dividend policies, showing similarity in shareholder return strategies and income potential for investors.
- ABBV Dividend Yield: 3%
- GILD Dividend Yield: 3%
A high score indicates similar approaches to returning capital to shareholders, suggesting comparable appeal to income-focused investors.
Income Statement
Financial Ratios
Growth
Johnson & Johnson
JNJ - NYQJohnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Gilead Sciences specializes in biopharmaceuticals and is focused on antiviral drugs, complementing J&J's extensive pharmaceutical and therapeutic product lines.
correlation
Measures how closely the two stocks' prices move together over time. A high correlation suggests similar market reactions and investor sentiment.
Pearson Correlation: 23%
R-squared: 5%
This indicates a negligible relationship between the price movements of these stocks.
network
Evaluates the overlap in business networks, partnerships, and industry relationships, indicating similarity in market positioning and competitive landscape.
- Common comparables: 5
- GILD in JNJ's comparables: Yes
- JNJ in GILD's comparables: No
A high score suggests the companies are often compared to each other and share many industry peers, indicating similar competitive environments and market perceptions.
financials
Compares key financial metrics to assess operational similarity and financial health.
- Revenue Growth: 6% vs 5%
- Profit Margin: 2% vs 16%
- ROE: 2% vs 20%
- Operating Margin: 33% vs 18%
- Revenue (TTM): $28.8B vs $88.8B
A high score indicates similar financial performance, efficiency, and growth trajectories, suggesting comparable business models and market positions.
size
Evaluates similarity in market capitalization, which can indicate comparable market influence, investor interest, and resource availability.
Market Cap: $143.8B vs $397.3B
Size Category: Large Cap vs Mega Cap
A high score suggests the companies are in the same size category, facing similar challenges and opportunities in terms of market presence and financial flexibility.
valuation
Compares valuation metrics to assess if the stocks are valued similarly by the market, indicating comparable investor expectations and perceived growth potential.
- P/E Ratio: 303.89 vs 28.50
- P/B Ratio: 7.39 vs 5.56
- EV/EBITDA: 35.64 vs 16.52
- Forward P/E: 14.51 vs 15.58
- PEG Ratio: 0.61 vs 1.12
A high score indicates that the market values these companies similarly relative to their financials, suggesting comparable growth expectations and risk profiles.
sector
Compares the sector and industry classification of both companies, allowing for partial matches.
- Sector: LIFE SCIENCES vs LIFE SCIENCES
- Industry: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) vs PHARMACEUTICAL PREPARATIONS
A high score indicates that the companies operate in similar business areas, facing comparable market conditions, regulatory environments, and industry trends. Partial matches are considered for more nuanced comparisons.
analyst ratings
Compares the consensus of analyst opinions on both stocks.
- GILD Rating: Buy
- JNJ Rating: Buy
A high score suggests that analysts view both stocks similarly in terms of their future prospects and investment potential.
geo
Evaluates the geographical similarity of the companies based on country, currency, exchange, and address.
- GILD Country: USA
- JNJ Country: USA
- Currency: USD vs USD
- Exchange: NMS vs NYQ
A high score indicates that both companies operate in similar geographical markets, facing comparable economic conditions, regulations, and market dynamics.
volatility
Compares price volatility and risk profiles, indicating similarity in market behavior, risk, and potential for price swings.
- GILD Beta: 0.24 (No Correlation)
- JNJ Beta: 0.51 (Low)
A high score suggests both stocks have similar sensitivity to market movements, implying comparable risk levels and potential for both gains and losses.
business similarity
Assesses the similarity of the companies' business models, products, and services.
This score is based on an analysis of the companies' business descriptions, major products, and revenue streams.
A high score indicates that the companies have similar core businesses, target markets, and revenue generation strategies.
momentum
Compares recent price momentum, showing similarity in short-term market performance and investor sentiment.
- GILD Price vs 200-day MA: 137.36%
- JNJ Price vs 200-day MA: 106.67%
A high score indicates both stocks are experiencing similar price trends relative to their recent history, suggesting comparable market enthusiasm or concern.
dividend
Compares dividend policies, showing similarity in shareholder return strategies and income potential for investors.
- GILD Dividend Yield: 3%
- JNJ Dividend Yield: 3%
A high score indicates similar approaches to returning capital to shareholders, suggesting comparable appeal to income-focused investors.
Income Statement
Financial Ratios
Growth
Bristol-Myers Squibb Company
BMY - NYQBristol Myers Squibb (BMS) is an American multinational pharmaceutical company, headquartered in New York City. Bristol Myers Squibb manufactures prescription pharmaceuticals and biologics in several therapeutic areas, including cancer, AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders.
Gilead Sciences Inc. specializes in antiviral drugs and has a strong oncology pipeline, positioning it as a comparable company to Bristol-Myers Squibb in the life sciences sector.
correlation
Measures how closely the two stocks' prices move together over time. A high correlation suggests similar market reactions and investor sentiment.
Pearson Correlation: 34%
R-squared: 12%
This indicates a weak positive relationship between the price movements of these stocks.
network
Evaluates the overlap in business networks, partnerships, and industry relationships, indicating similarity in market positioning and competitive landscape.
- Common comparables: 5
- BMY in GILD's comparables: Yes
- GILD in BMY's comparables: Yes
A high score suggests the companies are often compared to each other and share many industry peers, indicating similar competitive environments and market perceptions.
financials
Compares key financial metrics to assess operational similarity and financial health.
- Revenue Growth: 8% vs 6%
- Profit Margin: -19% vs 2%
- ROE: -39% vs 2%
- Operating Margin: 23% vs 33%
- Revenue (TTM): $48.3B vs $28.8B
A high score indicates similar financial performance, efficiency, and growth trajectories, suggesting comparable business models and market positions.
size
Evaluates similarity in market capitalization, which can indicate comparable market influence, investor interest, and resource availability.
Market Cap: $121.4B vs $143.8B
Size Category: Large Cap vs Large Cap
A high score suggests the companies are in the same size category, facing similar challenges and opportunities in terms of market presence and financial flexibility.
valuation
Compares valuation metrics to assess if the stocks are valued similarly by the market, indicating comparable investor expectations and perceived growth potential.
- P/E Ratio: 0.00 vs 303.89
- P/B Ratio: 7.38 vs 7.39
- EV/EBITDA: 50.81 vs 35.64
- Forward P/E: 8.76 vs 14.51
- PEG Ratio: 1.35 vs 0.61
A high score indicates that the market values these companies similarly relative to their financials, suggesting comparable growth expectations and risk profiles.
sector
Compares the sector and industry classification of both companies, allowing for partial matches.
- Sector: LIFE SCIENCES vs LIFE SCIENCES
- Industry: PHARMACEUTICAL PREPARATIONS vs BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
A high score indicates that the companies operate in similar business areas, facing comparable market conditions, regulatory environments, and industry trends. Partial matches are considered for more nuanced comparisons.
analyst ratings
Compares the consensus of analyst opinions on both stocks.
- BMY Rating: Hold
- GILD Rating: Buy
A high score suggests that analysts view both stocks similarly in terms of their future prospects and investment potential.
geo
Evaluates the geographical similarity of the companies based on country, currency, exchange, and address.
- BMY Country: USA
- GILD Country: USA
- Currency: USD vs USD
- Exchange: NYQ vs NMS
A high score indicates that both companies operate in similar geographical markets, facing comparable economic conditions, regulations, and market dynamics.
volatility
Compares price volatility and risk profiles, indicating similarity in market behavior, risk, and potential for price swings.
- BMY Beta: 0.44 (Low)
- GILD Beta: 0.24 (No Correlation)
A high score suggests both stocks have similar sensitivity to market movements, implying comparable risk levels and potential for both gains and losses.
business similarity
Assesses the similarity of the companies' business models, products, and services.
This score is based on an analysis of the companies' business descriptions, major products, and revenue streams.
A high score indicates that the companies have similar core businesses, target markets, and revenue generation strategies.
momentum
Compares recent price momentum, showing similarity in short-term market performance and investor sentiment.
- BMY Price vs 200-day MA: 116.77%
- GILD Price vs 200-day MA: 137.36%
A high score indicates both stocks are experiencing similar price trends relative to their recent history, suggesting comparable market enthusiasm or concern.
dividend
Compares dividend policies, showing similarity in shareholder return strategies and income potential for investors.
- BMY Dividend Yield: 4%
- GILD Dividend Yield: 3%
A high score indicates similar approaches to returning capital to shareholders, suggesting comparable appeal to income-focused investors.
Income Statement
Financial Ratios
Growth
Loading comparable stocks ...
AbbVie Inc.
ABBV - NYQAbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Johnson & Johnson
JNJ - NYQJohnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow...
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Bristol-Myers Squibb Company
BMY - NYQBristol Myers Squibb (BMS) is an American multinational pharmaceutical company, headquartered in New York City. Bristol Myers Squibb manufactures prescription pharmaceuticals and biologics in several...
Bristol Myers Squibb (BMS) is an American multinational pharmaceutical company, headquartered in New York City. Bristol Myers Squibb manufactures prescription pharmaceuticals and biologics in several therapeutic areas, including cancer, AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders.